RECOVERY / PEPTIDE CARD

BPC-157

A synthetic 15-amino-acid research peptide with extensive preclinical claims but little interpretable human efficacy evidence.

PEPTIDE CARDBPC-157

Reviewed
August 7, 2026

Human evidence

1/5 · Very limited

U.S. FDANot FDA approved

2026 WADAProhibited

Inspect 3 sources

On this page

WHAT THE EVIDENCE SAYS

BPC-157 evidence summary.

Interest in BPC-157 is driven by broad preclinical findings. The central evidence gap is not whether animal signals exist, but whether a defined product is safe and effective in people.

Entity type
Synthetic peptideSource snapshot
August 7, 2026Record status
Sources attached

Do not overread this record

Commercial descriptions often translate animal findings into human recovery claims. The evidence does not support that shortcut.

01 / CLASSIFICATION

What is BPC-157?

Entity typeSynthetic peptide

Research categoryRecovery

Known namesBPC-157

Editorial unitOne molecule or defined product record

Names, fragments, salts, formulations, routes, and branded products are kept distinct whenever transferring evidence would change the conclusion.

Class: Repair and extracellular-matrix peptides Goal: Recovery & Tissue Repair

02 / EVIDENCE

BPC-157 human and preclinical evidence.

HUMAN

1/5 · Very limited

No completed Phase II efficacy program and no reliable basis for routine clinical claims.

PRECLINICAL

4/5 · Extensive preclinical

A large animal and laboratory literature has not yet translated into established human benefit.

The five-point bars describe the maturity and depth of the evidence base. They do not score effectiveness, safety, or personal suitability.

03 / STATUS

BPC-157 FDA and sport status.

U.S. FDANot FDA approved; FDA identifies important compounding safety and characterization concerns.

2026 WADAProhibited at all times under the 2026 WADA List (S0).

Commercial accessPeptideAgent does not route unapproved research substances to sellers.

Status summaries are educational and time-sensitive. Consult current official labeling and anti-doping resources for a decision.

04 / RESEARCH AREAS

What is BPC-157 being studied for?

01Tissue repair

02Gastrointestinal models

03Inflammation

04Angiogenesis

05 / COMPARISONS

Compare BPC-157.

BPC-157 vs TB-500A source-backed comparison of two unapproved recovery-market peptides.BPC-157 vs Thymosin Beta-4Two tissue-repair research stories compared without translating preclinical signals into recovery claims.BPC-157 vs GHK-CuPreclinical recovery claims compared with limited route-specific topical human research.BPC-157 vs KPVTwo unapproved peptides discussed for inflammation and gastrointestinal research.

06 / LATEST & DEFINING SOURCES

BPC-157 primary and official sources.

FDA / 2026Bulk substances that may present significant safety risks

U.S. FDA

Review / 2026BPC-157 as an investigational peptide therapeutic

PubMed

WADA / 20262026 Prohibited List

World Anti-Doping Agency

07 / QUESTIONS

Questions about BPC-157.

Start with identity, research, human evidence, approval, sport status, and the limits of the current record.

EvidenceWhat is the evidence for BPC-157?

Interest in BPC-157 is driven by broad preclinical findings. The central evidence gap is not whether animal signals exist, but whether a defined product is safe and effective in people.

ResearchWhat is BPC-157 being studied for?

Current source-backed research areas include Tissue repair, Gastrointestinal models, Inflammation, Angiogenesis. These areas describe investigation, not established personal benefit.

FDA statusIs BPC-157 FDA approved?

Current U.S. status for BPC-157: Not FDA approved; FDA identifies important compounding safety and characterization concerns.

Sport statusIs BPC-157 prohibited in sport?

Current sport-status snapshot for BPC-157: Prohibited at all times under the 2026 WADA List (S0).

Evidence limitsWhat are the main evidence limits for BPC-157?

Commercial descriptions often translate animal findings into human recovery claims. The evidence does not support that shortcut.

Decision questionWhat is the evidence for BPC-157 and TB-500?

Both are promoted for recovery far beyond the human evidence. The main differences are the shape of the preclinical literature and the identity problem around TB-500.